IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Am J Gastroenterol. 2022 Nov 1;117(11):1825-1833. doi: 10.14309/ajg.0000000000001887. Epub 2022 Jul 21.
A noninvasive diagnosis of clinically significant portal hypertension (CSPH) has important prognostic and therapeutic implications for patients with compensated advanced chronic liver disease. We aimed to validate and improve the available algorithms for the CSPH diagnosis by evaluating spleen stiffness measurement (SSM) in patients with compensated advanced chronic liver disease.
This is a retrospective study including patients with liver stiffness measurement (LSM) ≥10 kPa, no previous decompensation, and available measurements of hepatic venous pressure gradient, LSM, and SSM by transient elastography referring to our center in Bologna. The diagnostic algorithms were adequate if negative and positive predictive values were >90% when ruling out and ruling in CSPH, respectively; these models were validated in a cohort from Verona. The 5-year decompensation rate was reported.
One hundred fourteen patients were included in the derivation cohort. The Baveno VII diagnostic algorithm (LSM ≤15 kPa + platelet count ≥150 × 10 9 /L to rule out CSPH and LSM >25 kPa to rule in CSPH) was validated; however, 40%-60% of the patients remained in the gray zone. The addition of SSM (40 kPa) to the model significantly reduced the gray zone to 7%-15%, maintaining adequate negative and positive predictive values. The diagnostic algorithms were validated in a cohort of 81 patients from Verona. All first decompensation events occurred in the "rule-in" zone of the model including SSM.
The addition of SSM significantly improves the clinical applicability of the algorithm based on LSM and platelet count for CSPH diagnosis. Our models can be used to noninvasively identify candidates for nonselective beta-blocker treatment and patients at a high risk of decompensation.
对于代偿期晚期慢性肝病患者,临床显著门静脉高压(CSPH)的非侵入性诊断具有重要的预后和治疗意义。我们旨在通过评估代偿期晚期慢性肝病患者的脾脏硬度测量(SSM)来验证和改进现有的 CSPH 诊断算法。
这是一项回顾性研究,包括 LSM≥10kPa、无既往失代偿且有肝静脉压力梯度、LSM 和瞬时弹性成像 SSM 测量值的患者。如果排除和纳入 CSPH 的阴性和阳性预测值分别>90%,则这些算法为合理;这些模型在博洛尼亚的一个队列中进行了验证。报告了 5 年的失代偿率。
114 例患者纳入推导队列。Baveno VII 诊断算法(LSM≤15kPa+血小板计数≥150×109/L 排除 CSPH,LSM>25kPa 纳入 CSPH)得到验证;然而,40%-60%的患者仍处于灰色地带。将 SSM(40kPa)添加到模型中,显著减少了灰色区域至 7%-15%,保持了足够的阴性和阳性预测值。该诊断算法在维罗纳的 81 例患者队列中得到验证。所有首次失代偿事件均发生在包括 SSM 的模型“纳入”区。
SSM 的加入显著提高了基于 LSM 和血小板计数的 CSPH 诊断算法的临床适用性。我们的模型可用于非侵入性地识别非选择性β受体阻滞剂治疗的候选者和高失代偿风险的患者。